Möbert J, Becker B F
Institute of Physiology, University of Munich, Germany.
J Am Coll Cardiol. 1998 Jun;31(7):1687-94. doi: 10.1016/s0735-1097(98)00158-2.
Postischemic contractile dysfunction in the heart may be due, in part, to isoprostanes, thought to accumulate during myocardial reperfusion. This study tested whether cyclooxygenase (COX) inhibitors increase the amount of isoprostanes and, consequently, lead to deterioration of postischemic heart function.
Isoprostanes are bioactive prostaglandin-like compounds that are formed in vivo directly by free radical-catalyzed peroxidation of arachidonic acid. In particular, 8-isoprostaglandin (PG) F2alpha is a potent vasoconstrictor.
Isolated working guinea pig hearts underwent 30-min low flow ischemia followed by reperfusion, 15 min in a nonworking mode and 20 min performing pressure-volume work. Hearts were perfused with or without 100 micromol/liter acetylsalicylic acid (ASA), 3 or 10 micromol/liter indomethacin or 1 micromol/liter SQ 29548, a thromboxane-A2 (TxA2) receptor antagonist able to abolish the vasoconstrictive actions of 8-iso-PGF2alpha. External heart work (EHW) and coronary resistance were compared before and after ischemia. Coronary release and tissue content of 8-iso-PGF2alpha were also determined.
During reperfusion, 8-iso-PGF2alpha release increased tenfold compared with the preischemic value in all groups. However, in ASA- and indomethacin-treated hearts, 8-iso-PGF2alpha levels were approximately 15-fold higher than in control hearts (5.4 vs. 0.35 pg/ml, respectively). Postischemic tissue levels of 8-iso-PGF2alpha were also markedly higher: 215 (indomethacin) and 301 (ASA) pg/ml g dry weight versus 43 pg/mg dry weight for control hearts (p < 0.05). Treatment of hearts with COX inhibitor led to a reduction in recovery of EHW (40% vs. 71%, p < 0.05) and seemed to be due to impaired myocardial oxygenation: Coronary venous oxygen was lower (67% of control values), whereas anaerobic metabolism (lactate release vs. pyruvate consumption) was enhanced. Coronary resistance was correspondingly elevated (164% of control values). SQ 29548 caused all variables to revert to control values.
These data demonstrate that in the guinea pig heart, COX-inhibiting drugs exacerbate loss of cardiac function after ischemia. The enhanced production of isoprostanes favors coronary vasoconstriction and leads to myocardial oxygen deprivation.
心脏缺血后收缩功能障碍可能部分归因于异前列腺素,其被认为在心肌再灌注期间会蓄积。本研究测试了环氧化酶(COX)抑制剂是否会增加异前列腺素的量,并因此导致缺血后心脏功能恶化。
异前列腺素是生物活性类前列腺素化合物,由花生四烯酸的自由基催化过氧化直接在体内形成。特别是,8-异前列腺素(PG)F2α是一种强效血管收缩剂。
将离体工作的豚鼠心脏进行30分钟的低流量缺血,随后进行再灌注,15分钟非工作模式以及20分钟进行压力-容积工作。心脏在有或没有100微摩尔/升乙酰水杨酸(ASA)、3或10微摩尔/升吲哚美辛或1微摩尔/升SQ 29548(一种能够消除8-异-PGF2α血管收缩作用的血栓素A2(TxA2)受体拮抗剂)的情况下进行灌注。比较缺血前后的心脏外部工作(EHW)和冠状动脉阻力。还测定了冠状动脉中8-异-PGF2α的释放量和组织含量。
在再灌注期间,所有组中8-异-PGF2α的释放量与缺血前值相比增加了10倍。然而,在接受ASA和吲哚美辛治疗的心脏中,8-异-PGF2α水平比对照心脏高约15倍(分别为5.4对0.35皮克/毫升)。缺血后组织中的8-异-PGF2α水平也明显更高:吲哚美辛组为215皮克/毫升干重,ASA组为301皮克/毫升干重,而对照心脏为43皮克/毫克干重(p<0.05)。用COX抑制剂处理心脏导致EHW恢复降低(40%对71%,p<0.05),这似乎是由于心肌氧合受损:冠状静脉血氧较低(为对照值的67%),而无氧代谢(乳酸释放与丙酮酸消耗)增强。冠状动脉阻力相应升高(为对照值的164%)。SQ 29548使所有变量恢复到对照值。
这些数据表明,在豚鼠心脏中,COX抑制药物会加重缺血后心脏功能的丧失。异前列腺素生成增加有利于冠状动脉收缩并导致心肌缺氧。